Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 4, 2008, Pages 1302-1317

  Ptak, Roger G ^a   Gallay, Philippe A ^b   Jochmans, Dirk ^c   Halestrap, Andrew P ^d   Ruegg, Urs T ^e   Pallansch, Luke A ^a,j   Bobardt, Michael D ^b   De Béthune, Marie Pierre ^c   Neyts, Johan ^f   De Clercq, Erik ^f   Dumont, Jean Maurice ^g   Scalfaro, Pietro ^g   Besseghir, Kamel ^g   Wenger, Roland M ^h   Rosenwirth, Brigitte ⁱ  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c TIBOTEC BVBA   (Belgium)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF GENEVA   (Switzerland)

^f REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^g DEBIOPHARM SA   (Switzerland)

^h Wenger Chemtech   (Switzerland)

ⁱ UNIVERSITY OF VIENNA   (Austria)

^j Cell Trends Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; CAPSID PROTEIN; CYCLOPHILIN; CYCLOSPORIN; DEBIO 025; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BINDING; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; IN VIVO STUDY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE;

CELL LINE; CYCLOPHILINS; CYCLOSPORINE; HIV-1; HUMANS; JURKAT CELLS; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; VIRUS REPLICATION;

EID: 42049124062     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01324-07     Document Type: Article

References (106)

1. Aberham, C., S. Weber, and W. Phares. 1996. Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins. J. Virol. 70:3536-3544.
2. Andrei, G., R. Sienaert, C. McGuigan, E. De Clercq, J. Balzarini, and R. Snoeck. 2005. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob. Agents Chemother. 49:1081-1086.
3. Andrei, G., R. Snoeck, J. Piette, P. Delvenne, and E. De Clercq. 1998. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol. Res. 10:523-531.
4. Andrieu, J. M., P. Even, and A. Venet. 1986. AIDS and related syndromes as a viral-induced autoimmune disease of the immune system: an anti-MHC II disorder. Therapeutic implications. AIDS Res. 2:163-174.
5. Balzarini, J., E. Keyaerts, L. Vijgen, H. Egberink, E. De Clercq, M. Van Ranst, S. S. Printsevskaya, E. N. Olsufyeva, S. E. Solovieva, and M. N. Preobrazhenskaya. 2006. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antivir. Res. 72:20-33.
6. Bare, J., J.-M. Dumont, K. Besseghir, and C. Stoddart. 2004. Potent in vivo anti-HIV-1 activity of the nonimmunosuppressive cyclosporine UNIL-025, abstr. 110. Keystone Symp. HIV Pathogenesis.
7. Bartz, S. R., E. Hohenwalter, M. K. Hu, D. H. Rich, and M. Malkovsky. 1995. Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc. Natl. Acad. Sci. USA 92:5381-5385.
8. Baumann, G., G. Zenke, R. Wenger, P. Hiestand, V. Quesniaux, E. Andersen, and M. H. Schreier. 1992. Molecular mechanisms of immunosuppression. J. Autoimmun. 5(Suppl. A):67-72.
9. Besnier, C., Y. Takeuchi, and G. Towers. 2002. Restriction of lentivirus in monkeys. Proc. Natl. Acad. Sci. USA 99:11920-11925.
10. Billich, A., F. Hammerschmid, P. Peichl, R. Wenger, G. Zenke, V. Quesniaux, and B. Rosenwirth. 1995. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J. Virol. 69:2451-2461.
11. Borel, J. F., F. Di Padova, J. Mason, V. Quesniaux, B. Ryffel, and R. Wenger. 1989. Pharmacology of cyclosporine (Sandimmune). Pharmacol. Rev. 41:239-242.
12. Braaten, D., C. Aberham, E. K. Franke, L. Yin, W. Phares, and J. Luban. 1996. Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that gag encodes the functional target of cyclophilin A. J. Virol. 70:5170-5176.
13. Braaten, D., E. K. Franke, and J. Luban. 1996. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J. Virol. 70:3551-3560.
14. Braaten, D., E. K. Franke, and J. Luban. 1996. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. J. Virol. 70:4220-4227.
15. Braaten, D., and J. Luban. 2001. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J. 20:1300-1309.
16. Buckheit, R. W., Jr., and R. Swanstrom. 1991. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res. Hum. Retrovir. 7:295-302.
17. Bukovsky, A. A., A. Weimann, M. A. Accola, and H. G. Gottlinger. 1997. Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence. Proc. Natl. Acad. Sci. USA 94:10943-10948.
18. Butler, S. L., M. S. Hansen, and F. D. Bushman. 2001. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7:631-634.
19. Chatterji, U., M. D. Bobardt, R. Stanfield, R. G. Ptak, L. A. Pallansch, P. A. Ward, M. J. Jones, C. A. Stoddart, P. Scalfaro, J. M. Dumont, K. Besseghir, B. Rosenwirth, and P. A. Gallay. 2005. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in owl monkey cells. J. Biol. Chem. 280:40293-40300.
20. Cheung, P. K., B. Wynhoven, and P. R. Harrigan. 2004. 2004: which HIV-1 drug resistance mutations are common in clinical practice? AIDS Rev. 6:107-116.
21. Damaso, C. R., and N. Moussatche. 1998. Inhibition of vaccinia virus replication by cyclosporin A analogues correlates with their affinity for cellular cyclophilins. J. Gen. Virol. 79:339-346.
22. De Clercq, E. 2005. Emerging anti-HIV drugs. Expert Opin. Emerg. Drugs 10:241-273.
23. DeJesus, E., D. Berger, M. Markowitz, C. Cohen, T. Hawkins, P. Ruane, R. Elion, C. Farthing, L. Zhong, A. K. Cheng, D. McColl, and B. P. Kearny for the 183-0101 Study Team. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43:1-5.
24. Dorr, P., M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickell. C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, and M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
25. Dreyfuss, M., E. Harri, H. Hoffmann, H. Kobel, W. Pache, and H. Tscherter. 1976. Cyclosporin A and C. New metabolites from Trichoderma polysporum. Eur. J. Appl. Microbiol. 3:125-133.
26. Eisenmesser, E. Z., O. Millet, W. Labeikovsky, D. M. Korzhnev, M. Wolf-Watz, D. A. Bosco, J. J. Skalicky, L. E. Kay, and D. Kern. 2005. Intrinsic dynamics of an enzyme underlies catalysis. Nature 438:117-121.
27. Fischer, G., H. Bang, and C. Mech. 1984. Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides. Biomed. Biochim. Acta 43:1101-1111.
28. Flisiak R., A. Horban, P. Gallay, M. Bobardt, S. Selvarajah, A. Wiercinska-Drapalo, E. Siwak, I. Cielniak, J. Higersberger, J. Kierkus, C. Aeschlimann, P. Grosgurin, V. Nicolas-Metral, J.-M. Dumont, H. Porchet, R. Crabbe, and P. Scalfaro. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in human immunodeficiency virus co-infected hepatitis C patients. Hepatology, in press.
29. Flisiak, R., A. Horban, J. Kierkus, J. Stanczak, I. Cielniak, G. P. Stanczak, A. Wiercinska-Drapalo, E. Siwak, J. Higersberger, C. Aeschlimann, P. Grosgurin, V. Nicolas, J.-M. Dumont, H. Porchet, R. Crabbe, and P. Scalfaro. 2006. The cyclophilin inhibitor Debio-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naive HIV/HCV co-infected subjects. Hepatology 44(Suppl. 1):609A.
30. Franke, E. K., H. E. Yuan, and J. Luban. 1994. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372:359-362.
31. Gamble, T. R., F. F. Vajdos, S. Yoo, D. K. Worthylake, M. Houseweart, W. I. Sundquist, and C. P. Hill. 1996. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87:1285-1294.
32. Garcia-Echverria, C., J. L. Kofron, P. Kuzmic, and D. H. Rich. 1993. A continuous spectrophotometric direct assay for peptidyl prolyl cis-trans isomerases. Biochem. Biophys. Res. Commun. 191:70-75.
33. Gatanaga, H., D. Das, Y. Suzuki, D. D. Yeh, K. A. Hussain, A. K. Ghosh, and H. Mitsuya. 2006. Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop. J. Biol. Chem. 281:1241-1250.
34. Grinsztejn, B., B. Y. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin, D. Vittecoq, C. J. Gonzalez, J. Chen, C. M. Harvey, and R. D. Isaacs. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269.
35. Handschumacher, R. E., M. W. Harding, J. Rice, R. J. Drugge, and D. W. Speicher. 1984. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 226:544-546.
36. Hatziioannou, T., S. Cowan, U. K. Von Schwedler, W. I. Sundquist, and P. D. Bieniasz. 2004. Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. J. Virol. 78:6005-6012.
37. Hatziioannou, T., D. Perez-Caballero, S. Cowan, and P. D. Bieniasz. 2005. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J. Virol. 79:176-183.
38. Hermann, E., R. Flisiak, A. Horban, R. Crabbe, H. Porchet, V. Nicolas, P. Scalfaro, and S. Zeuzem. 2007. Viral kinetics during 14-day treatment with Debio-025 demonstrate efficient blocking of viral replication in different HCV genotypes without signs of emerging viral resistance. J. Hepatol. 46(Suppl. 1):S40.
39. Herzyk, D. J., and E. R. Gore. 2004. Adequate immunotoxicity testing in drug development. Toxicol. Lett. 149:115-122.
40. Huai, Q., H. Y. Kim, Y. Liu, Y. Zhao, A. Mondragon, J. O. Liu, and H. Ke. 2002. Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc. Natl. Acad. Sci. USA 99:12037-12042.
41. Hubler, F., T. Ruckle, L. Patiny, T. Muamba, J. F. Guichou, M. Mutter, and R. Wenger. 2000. Synthetic routes to NEtXaa4-cyclosporin A derivates as potential anti-HIV drugs. Tetrahedron Lett. 41:7193-7196.
42. Ikeda, Y., L. M. Ylinen, M. Kahar-Bador, and G. J. Towers. 2004. Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J. Virol. 78:11816-11822.
43. Jin, L., and S. C. Harrison. 2002. Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc. Natl. Acad. Sci. USA 99:13522-13526.
44. Kootstra, N. A., C. Munk, N. Tonnu, N. R. Landau, and I. M. Verma. 2003. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc. Natl. Acad. Sci. USA 100:1298-1303.
45. Kronke, M., W. J. Leonhard, J. M. Depper, S. K. Arya, F. Wong-Staal, R. C. Gallo, T. A. Waldmann, and W. C. Greene. 1984. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc. Natl. Acad. Sci. USA 81:5214-5218.
46. Lebeau, I., G. Andrei, F. Dal Pozzo, J. R. Beadle, K. Y. Hostetler, E. De Clercq, J. van den Oord, and R. Snoeck. 2006. Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonyl- methoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrob. Agents Chemother. 50:2525-2529.
47. Luban, J. 2007. Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J. Virol. 81:1054-1061.
48. Luban, J., K. L. Bossolt, E. K. Franke, G. V. Kalpana, and S. P. Goff. 1993. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73:1067-1078.
49. Meo, T. 1979. The MLR test in the mouse, p. 227-239. In I. Lefkovitz and B. Pernis (ed.), Immunological methods. Academic Press, Inc., New York, NY.
50. Miyoshi, I., S. Yoshimoto, I. Kubonishi, H. Taguchi, Y. Shiraishi, Y. Ohtsuki, and T. Akagi. 1981. Transformation of normal human cord lymphocytes by co-cultivation with a lethally irradiated human T-cell line carrying type C virus particles. Gann 72:997-998.
51. Mlynar, E., D. Bevec, A. Billich, B. Rosenwirth, and A. Steinkasserer. 1997. The non-immunosuppressive cyclosporin A analogue SDZ NIM 811 inhibits cyclophilin A incorporation into virions and virus replication in human immunodeficiency virus type 1-infected primary and growth-arrested T cells. J. Gen. Virol. 78:825-835.
52. Nakagawa, M., N. Sakamoto, N. Enomoto, Y. Tanabe, N. Kanazawa, T. Koyama, M. Kurosaki, S. Maekawa, T. Yamashiro, C. H. Chen, Y. Itsui, S. Kakinuma, and M. Watanabe. 2004. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem. Biophys. Res. Commun. 313:42-47.
53. Nara, P. L., W. C. Hatch, N. M. Dunlop, W. G. Robey, L. O. Arthur, M. A. Gonda, and P. J. Fischinger. 1987. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res. Hum. Retrovir. 3:283-302.
54. Neyts, J., A. Meerbach, P. McKenna, and E. De Clercq. 1996. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antivir. Res. 30:125-132.
55. Neyts, J., D. Reymen, D. Letourneur, J. Jozefonvicz, D. Schols, J. Este, G. Andrei, P. McKenna, M. Witvrouw, S. Ikeda, J. Clement, and E. De Clercq. 1995. Differential antiviral activity of derivatized dextrans. Biochem. Pharmacol. 50:743-751.
56. Ou, C. Y., S. Kwok, S. W. Mitchell, D. H. Mack, J. J. Sninsky, J. W. Krebs, P. Feorino, D. Warfield, and G. Schochetman. 1988. DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 239:295-297.
57. Owens, C. M., B. Song, M. J. Perron, P. C. Yang, M. Stremlau, and J. Sodroski. 2004. Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J. Virol. 78:5423-5437.
58. Owens, C. M., P. C. Yang, H. Gottlinger, and J. Sodroski. 2003. Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J. Virol. 77:726-731.
59. Paeshuyse, J., J. M. Chezal, M. Froeyen, P. Leyssen, H. Dutartre, R. Vrancken, B. Canard, C. Letellier, T. Li, H. Mittendorfer, F. Koenen, P. Kerkhofs, E. De Clercq, P. Herdewijn, G. Puerstinger, A. Gueiffier, O. Chavignon, J. C. Teulade, and J. Neyts. 2007. The imidazopyrrolopyridine analogue AG110 is a novel, highly selective inhibitor of pestiviruses that targets the viral RNA-dependent RNA polymerase at a hot spot for inhibition of viral replication. J. Virol. 81:11046-11053.
60. Paeshuyse, J., A. Kaul, E. De Clercq, B. Rosenwirth, J. M. Dumont, P. Scalfaro, R. Bartenschlager, and J. Neyts. 2006. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43:761-770.
61. Palmer, S., R. W. Shafer, and T. C. Merigan. 1999. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 13:661-667.
62. Papageorgiou, C., X. Borer, and R. R. French. 1994. Calcineurin has a very tight-binding pocket for the side chain of residue 4 of cyclosporin. Bioorg. Med. Chem. Lett. 4:267-272.
63. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
64. Phillips, A., M. A. Wainberg, R. Coates, M. Klein, A. Rachlis, S. Read, F. Shepherd, H. Vellend, S. Walmsley, P. Halloran, and M. Fanning. 1989. Cyclosporine-induced deterioration in patients with AIDS. CMAJ 140:1456-1460.
65. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-206.
66. Quesniaux, V. F., M. H. Schreier, R. M. Wenger, P. C. Hiestand, M. W. Harding, and M. H. Van Regenmortel. 1987. Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity. Eur. J. Immunol. 17:1359-1365.
67. Rits, M. A., K. A. van Dort, C. Munk, A. B. Meijer, and N. A. Kootstra. 2007. Efficient transduction of simian cells by HIV-1-based lentiviral vectors that contain mutations in the capsid protein. Mol. Ther. 15:930-937.
68. Rosenwirth, B., A. Billich, R. Datema, P. Donatsch, F. Hammerschmid, R. Harrison, P. Hiestand, H. Jaksche, P. Mayer, P. Peichl, V. Quesniaux, F. Schatz, H. J. Schuurmann, R. Traber, R. Wenger, B. Wolff, G. Zenke, and M. Zurini. 1994. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob. Agents Chemother. 38:1763-1772.
69. Rosenwirth, B., A. Billich, A. Steinkasserer, F. Hammerschmid, P. Peichl, H. Göttlinger, R. Traber, and R. Wenger. 1995. Cyclophilin A as a novel target in anti-HIV-1 chemotherapy. Int. Antivir. News 3:62-63.
70. Rosenwirth, B., A. Billich, A. Steinkasserer, P. Peichl, P. Donatsch, A. Lawen, R. Wenger, and R. Traber. 1995. SDZ NIM 811: anti-HIV nonimmunosuppressive natural cyclosporin. Drugs Future 20:579-583.
71. Ruegger, A., M. Kuhn, H. Lichti, H. R. Loosli, R. Huguenin, C. Quiquerez, and A. von Wartburg. 1976. Cyclosporin A, ein immunosuppressiv wirksamer Peptidmetabolit aus Trichoderma polysporum. Helv. Chim. Acta 59:1075-1092.
72. Saini, M., and M. J. Potash. 2006. Novel activities of cyclophilin A and cyclosporin A during HIV-1 infection of primary lymphocytes and macrophages. J. Immunol. 177:443-449.
73. Sayah, D. M., and J. Luban. 2004. Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection. J. Virol. 78:12066-12070.
74. Sayah, D. M., E. Sokolskaja, L. Berthoux, and J. Luban. 2004. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430:569-573.
75. Schwarz, A., G. Offermann, F. Keller, I. Bennhold, J. L'Age-Stehr, P. H. Krause, and M. J. Mihatsch. 1993. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation - data on four cases and review of the literature. Transplantation 55:95-103.
76. Siddiqi, S. M., X. Chen, S. W. Schneller, S. Ikeda, R. Snoeck, G. Andrei, J. Balzarini, and E. De Clercq. 1994. An epimer of 5′-noraristeromycin and its antiviral properties. J. Med. Chem. 37:1382-1384.
77. Snoeck, R., T. Sakuma, E. De Clercq, I. Rosenberg, and A. Holy. 1988. (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 32:1839-1844.
78. Snyder, S. H., and D. M. Sabatini. 1995. Immunophilins and the nervous system. Nat. Med. 1:32-37.
79. Sokolskaja, E., L. Berthoux, and J. Luban. 2006. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J. Virol. 80:2855-2862.
80. Sokolskaja, E., and J. Luban. 2006. Cyclophilin, TRIM5, and innate immunity to HIV-1. Curr. Opin. Microbiol. 9:404-408.
81. Sokolskaja, E., D. M. Sayah, and J. Luban. 2004. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J. Virol. 78:12800-12808.
82. Steinkasserer, A., R. Harrison, A. Billich, F. Hammerschmid, G. Werner, B. Wolff, P. Peichl, G. Palfi, W. Schnitzel, E. Mlynar, and B. Rosenwirth. 1995. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication. J. Virol. 69:814-824.
83. Steyn, D., D. Richman, C. Aeschlimann, J.-M. Dumont, P. Grosgurin, B. Rosenwirth, C. Loveday, H. Porchet, V. Nicolas, and P. Scalfaro. 2006. A double-blind placebo-controlled study in HIV-1-infected subjects on the safety, pharmacokinetics and antiviral effect of cyclophilin A targeting Debio-025, abstr. 516. 13th Conf. Retrovir. Opportunistic Infect.
84. Stremlau, M., C. M. Owens, M. J. Perron, M. Kiessling, P. Autissier, and J. Sodroski. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.
85. Stremlau, M., B. Song, H. Javanbakht, M. Perron, and J. Sodroski. 2006. Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. Virology 351:112-120.
86. Strizki, J. M., C. Tremblay, S. Xu, L. Wojcik, N. Wagner, W. Gonsiorek, R. W. Hipkin, C. C. Chou, C. Pugliese-Sivo, Y. Xiao, J. R. Tagat, K. Cox, T. Priestley, S. Sorata, W. Huang, M. Hirsch, G. R. Reyes, and B. M. Baroudy. 2005. Discovery and characterization of Vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49:4911-4919.
87. Thali, M., A. Bukovsky, E. Kondo, B. Rosenwirth, C. T. Walsh, J. Sodroski, and H. G. Gottlinger. 1994. Functional association of cyclophilin A with HIV-1 virions. Nature 372:363-365.
88. Towers, G. J., T. Hatziioannou, S. Cowan, S. P. Goff, J. Luban, and P. D. Bieniasz. 2003. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. 9:1138-1143.
89. 4] cyclosporin, a novel natural cyclosporin with anti-HIV activity. Antivir. Chem. Chemother. 5:331-339.
90. Vella, S., and L. Palmisano. 2000. Antiretroviral therapy: state of the HAART. Antivir. Res. 45:1-7.
91. Wainberg, M. A., A. Dascal, N. Blain, L. Fitz-Gibbon, F. Boulerice, K. Numazaki, and M. Tremblay. 1988. The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1. Blood 72:1904-1910.
92. Watashi, K., M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno. 2003. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282-1288.
93. Watashi, K., N. Ishii, M. Hijikata, D. Inoue, T. Murata, Y. Miyanari, and K. Shimotohno. 2005. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell 19:111-122.
94. Weber, C., G. Wider, B. Von Freyberg, R. Traber, W. Braun, H. Widmer, and K. Wuthrich. 1991. The NMR structure of cyclosporin A bound to cyclophilin in aqueous solution. Biochemistry 30:6563-6574.
95. Weiss, A., R. L. Wiskocil, and J. D. Stobo. 1984. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J. Immunol. 133:123-128.
96. Wenger, R. M. 1986. Cyclosporine and analogues - isolation and synthesis - mechanism of action and structural requirements for pharmacological activity. Fortschr. Chem. Org. Naturst. 50:123-136.
97. Wenger, R. M., M. Mutter, and T. Ruckle. January 2000. Novel cyclosporin with improved activity profile. Patent WO 00/01715. U.S. patent 6,927,208 B1, August 2005.
98. Wenger, R. M., T. G. Payne, and M. H. Schreier. 1985. Cyclosporine: chemistry, structure-activity relationships and mode of action. Prog. Clin. Biochem. Med. 3:157-191.
99. Westby, M., M. Lewis, J. Whitcomb, M. Youle, A. L. Pozniak, I. T. James, T. M. Jenkins, M. Perros, and E. van der Ryst. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80:4909-4920.
100. Wiegers, K., and H. G. Kräusslich. 2002. Differential dependence of the infectivity of HIV-1 group O isolates on the cellular protein cyclophilin A. Virology 294:289-295.
101. Yamashita, M., and M. Emerman. 2004. Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J. Virol. 78:5670-5678.
102. Yang, R., and C. Aiken. 2007. A mutation in alpha helix 3 of CA renders human immunodeficiency virus type 1 cyclosporin A resistant and dependent: rescue by a second-site substitution in a distal region of CA. J. Virol. 81:3749-3756.
103. Yin, L., D. Braaten, and J. Luban. 1998. Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J. Virol. 72:6430-6436.
104. Ying, C., A. Holy, D. Hockova, Z. Havlas, E. De Clercq, and J. Neyts. 2005. Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities. Antimicrob. Agents Chemother. 49:1177-1180.
105. Zenke, G., G. Baumann, R. Wenger, P. Hiestand, V. Quesniaux, E. Andersen, and M. H. Schreier. 1993. Molecular mechanisms of immunosuppression by cyclosporins. Ann. N. Y. Acad. Sci. 685:330-335.
106. Zoidis, G., N. Kolocouris, G. B. Foscolos, A. Kolocouris, G. Fytas, P. Karayannis, E. Padalko, J. Neyts, and E. De Clercq. 2003. Are the 2-isomers of the drug rimantadine active anti-influenza A agents? Antivir. Chem. Chemother. 14:153-164.